EP2764099A1 - Composition d'ecm, plateforme à microenvironnement tumoral et leurs procédés - Google Patents

Composition d'ecm, plateforme à microenvironnement tumoral et leurs procédés

Info

Publication number
EP2764099A1
EP2764099A1 EP12838648.9A EP12838648A EP2764099A1 EP 2764099 A1 EP2764099 A1 EP 2764099A1 EP 12838648 A EP12838648 A EP 12838648A EP 2764099 A1 EP2764099 A1 EP 2764099A1
Authority
EP
European Patent Office
Prior art keywords
tumor
response
assay
tissue
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12838648.9A
Other languages
German (de)
English (en)
Other versions
EP2764099B1 (fr
EP2764099A4 (fr
Inventor
Mallikarjun Sundaram
Biswanath MAJUMDER
Misti JAIN
Saravanan THIAGARAJAN
Dency PINTO
Padhma RADHAKRISHNAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitra Rxdx India Private Ltd
Original Assignee
MITRA BIOTECH PRIVATE Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MITRA BIOTECH PRIVATE Ltd filed Critical MITRA BIOTECH PRIVATE Ltd
Publication of EP2764099A1 publication Critical patent/EP2764099A1/fr
Publication of EP2764099A4 publication Critical patent/EP2764099A4/fr
Application granted granted Critical
Publication of EP2764099B1 publication Critical patent/EP2764099B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • This application relates to the field of cancer and the development of prognostics and therapeutics for cancer. More specifically, the invention provides for Extra Cellular Matrix [ECM] composition, tumor microenvironment platform for culturing tumor tissue and methods thereof.
  • ECM Extra Cellular Matrix
  • the present disclosure relates to a 'Clinical response predictor' and its application in various cancers for chemotherapy, targeted, biological drugs and broadly agents that have anti-tumor effect.
  • the present disclosure further relates to a method for long term culture of tumor tissue, wherein said culture provides human ligands and tumor tissue micro-environment to mimic physiologically relevant signalling systems.
  • the disclosure further relates to a method for screening tumor tissue for the presence of specific markers for determining the viability of said cells for indication of tumor status.
  • the disclosure also relates to method of predicting response of a tumor subject and method of screening or developing anti-cancer agent.
  • Her2 is a protein as well as a gene based marker that segregates the patients who over express the protein Her2 from those who under express them. Detailed clinical investigation has been carried out in turn to show that those who have higher levels of the Her2 protein respond significantly better to the monoclonal antibody Herceptin In this context Her2 has been approved as a "Biomarker" to predict the outcome of Herceptin treatment for the patient under consideration.
  • biomarkers such as EGFR, C-MET whose presence or absence, or the expression profile is used to predict the efficacy of the targeted drugs under consideration.
  • EGFR epidermal growth factor
  • C-MET whose presence or absence, or the expression profile is used to predict the efficacy of the targeted drugs under consideration.
  • both the axis of an XY plane need to be defined; i.e., one needs to define the quantity or quality of the biomarker on one axis, and the clinical response on the other axis.
  • the biomarker Prior to the use of the biomarker, one needs to develop an extensive amount of data for the fixed combination of the quality &/ or quantity of the biomarker as well as the clinical outcome.
  • biomarker driven approach is largely constrained by many input factors such as the drug used, the disease in which it is used, and the biomarker that is used.
  • HPV positive patients who also have Head & Neck squamous cell carcinoma respond to chemotherapy better than HPV negative Head & Neck squamous cell carcinoma patients.
  • patients' HPV status is used as a gauge to predict their response to drugs for Head & neck squamous cell carcinoma in the event that they do develop Head & neck Squamous cell carcinoma.
  • patient's tumor sample is taken, homogenised into tumor cells, and this system is treated with various chemotherapeutics in in vitro system.
  • patient's tumor sample is treated with various chemotherapeutics in in vitro system without homogenization.
  • These in vitro tests come under different names (eg. Monolayer assay or clonogenic assay from Oncotest GMBH, chemosensitivity assay from Chemofx, Extreme Drug Resistance (EDR) test from Oncotech).
  • EDR Extreme Drug Resistance
  • peri-tumoral tissues in tumor maintenance includes the presence of genetic mutations in the stroma of several types of cancers and the role played by stromal cells in the acquisition of resistance to therapy.
  • stromal cells For a cultured tumor to be representative of actual cancer, it is essential that the tumor, as it proliferates in vitro, maintain its tissue organization and structure, its oncogenic properties, its differentiated functions, and any cellular heterogeneity that may have been present in vivo. If human tumors growing in vitro can satisfy the above criteria and, in addition, can be grown at high frequency for long periods of time in culture, they should prove valuable for basic studies in cancer biology as well as for clinically relevant testing.
  • the instant disclosure relates to developing a systems biology approach to create an in vitro patient segregation tool that mimics human tumor microenvironment on plate and hence results in potential applications in different fields of cancer treatment, both in prognostics as well as translational biology.
  • the instant disclosure also confirms the hypothesis with several examples both for prognostics as well as for translational biology applications.
  • the use of the patient segregation tool of the instant disclosure is also applicable in the development of prognostic, companion diagnostic, and translational biology applications for auto-immune disorders and inflammatory diseases.
  • the present disclosure relates to an Extra Cellular Matrix [ECM] composition
  • an Extra Cellular Matrix [ECM] composition comprising at least three components selected from group having collagen 1, collagen 3, collagen 4, collagen 6, Fibronectin, Vitronectin, Cadherin, Filamin A, Vimentin, Laminin, Decorin, Tenascin C, Osteopontin, Basement membrane proteins, Cytoskeletal proteins and Matrix proteins; a method to obtain Extra Cellular Matrix [ECM] composition as above, said method comprises acts of - a) subjecting tumor tissue to biochemical assay to identify components of the ECM, b) combining the components of the ECM selected from group of collagen 1, collagen 3, collagen 4, collagen 6, Fibronectin, VitroNectin, Cadherin, FilaminA, Vimentin, Laminin, Decorin, Tenascin C, Osteopontin, Basement membrane proteins, Cytoskeletal proteins and Matrix proteins to obtain the ECM composition; and a tumor microenvironment platform
  • Figure 1 shows schematic diagram depicting the development and validation of "Clinical Response Predictor” technology.
  • Figure 2 shows importance of paracrine factors in explant model.
  • Figure 3A shows importance of Extracellular matrix in explant model and 3B shows importance of microenvironment in explant model.
  • Figure 4A-G shows autologous ligands and Extra Cellular Matix retain the microenvironment and signaling network of patient tumors in culture. Image magnification: 20X.
  • Figure 5A-C shows the composition of ECM and its effects on the viability and proliferation.
  • Figure 6 shows comparison of the effects of different TPM on proliferation and activating cancer signaling proteins.
  • Figure 7A-C shows that early passages of human tumor xenografts retain molecular characteristics of original patient tumors.
  • Figure 8A-C shows that patient tumor and the xenograft derived from the same exhibit identical response outcome to anti-cancer therapy when tested in a tumor explant culture model.
  • Figure 9A-H shows that antitumor effects of TPF and Cetuximab on patient tumor explant culture is similar to response of human tumor xenografts as tested by in vivo efficacy experiments.
  • Figure 10 shows correlation of "Clinical Response Predictor” guided drug response platform with efficacy in vivo.
  • Figure 11 shows a schematic diagram depicting the development and validation of "Clinical Response Predictor” technology.
  • Figure 12 shows the clinical validation of "clinical response predictor” analysis data in Head and Neck Cancer. M score is calculated using “clinical response predictor” and predicted outcome is correlated with clinical outcome of patient. M-score of greater than 60 is obtained for 30 patients tumors and these patients are predicted to have complete response and over 90% of these patients indeed had clinical outcome matching "clinical response predictor” analysis. Similarly about 29 patients with M-score less than 25 are predicted to be non-responders and 100%) of the patients showed non-response post treatment.
  • Figure 13A-S shows the efficacy data obtained by "Clinical Response Predictor” Analysis for cancer patients treated with drugs or combinations of drugs.
  • the present disclosure relates to an Extra Cellular Matrix [ECM] composition
  • ECM Extra Cellular Matrix
  • ECM Extra Cellular Matrix
  • the present disclosure also relates to a method to obtain Extra Cellular Matrix [ECM] composition as mentioned above, said method comprises acts of:
  • the present disclosure also relates to a tumor microenvironment platform for culturing tumor tissue, said microenvironment comprising ECM composition as mentioned above, culture medium optionally alongwith serum, plasma or autologous PBMCs and drug.
  • the present disclosure also relates to a method for obtaining tumor microenvironment platform for culturing tumor tissue, said method comprising act of coating platform with ECM composition as mentioned above and adding culture medium optionally alongwith serum, plasma or autologous PBMCs and drug, to the platform to obtain the tumor microenvironment platform.
  • the present disclosure also relates to a method of organotypic culturing of tumor tissue, said method comprising act of culturing the tumor tissue on tumor microenvironment platform as mentioned above to obtain the organotypic culture.
  • the present disclosure also relates to a method of predicting response of a tumor subject to drug(s), said method comprising acts of:
  • the present disclosure also relates to a method of predicting response of a tumor subject to drug(s), said method comprising acts of:
  • the present disclosure also relates to a method of screening or developing anti-cancer agent, said method comprising acts of: a. culturing subject's tumor tissue on tumor micro environment platform as claimed in claim 3, to obtain cultured tumor tissue;
  • the present disclosure also relates to a method for screening tumor cells for specific markers, said method comprising act of:
  • the Extra Cellular Matrix [ECM] composition is tumor specific.
  • the collagen 1 is at concentration ranging from about 0.01 ⁇ g/ml to about 100 ⁇ g/ml, preferably at about 5 ⁇ g/ml or about 20 ⁇ g/ml or about 50 ⁇ g/ml;
  • the collagen 3 is at concentration ranging from about 0.01 ⁇ g/ml to about 100 ⁇ g/ml, preferably at about 0.1 ⁇ g/ml or about 1 ⁇ g/ml or about 100 ⁇ g/ml;
  • the collagen 4 is at concentration ranging from about 0.01 ⁇ g/ml to about 500 ⁇ g/ml, preferably at about 5 ⁇ g/ml or about 20 ⁇ g/ml or about 250 ⁇ g/ml;
  • the collagen 6 is at concentration ranging from about 0.01 ⁇ g/ml to about 500 ⁇ g/ml, preferably at about 0.1 ⁇ g/ml or about 1 ⁇ g/ml or about 10 ⁇ g/ml;
  • the Fibronectin is at concentration ranging from about
  • said tumor tissue is obtained from source selected from group comprising central nervous system, bone marrow, blood, spleen, thymus, heart, mammary gland, liver, pancreas, thyroid, skeletal muscle, kidney, lung, intestine, stomach, oesophagus, ovary, bladder, testis, uterus, stromal tissue and connective tissue or any combinations thereof.
  • the tumor or the tumor tissue is obtained surgically or by biopsy or as xenograft or any combinations thereof; and the tumor or the tumor tissue is divided into small pieces of about 100 ⁇ to about 3000 ⁇ sections.
  • the culturing of the tumor tissue is carried out at temperature ranging from about 30°C to about 40°C, preferably about 37°C; for time duration of about 2 to 10 days, preferably about 3 to 7 days; and about 5% C0 2 .
  • the tumor microenvironment platform is selected from group comprising plate, base, flask, dish, petriplate and petridish.
  • said platform is for maintaining signaling networks of tumor cell.
  • said platform is for maintaining an intact tissue micro-environment, cellular architecture and integrity of tumor-stroma interaction.
  • the culture medium is selected from group comprising Dulbecco's Modified Eagle Medium [DMEM] or RPMI1640 [Roswell Park Memorial Institute Medium] at concentration ranging from about 60% to about 100%, preferably about 80% 2ml; heat inactivated FBS (Foetal Bovine Serum) at concentration ranging from about 0.1% to about 40%, preferably about 2% wt/wt; Penicillin-Streptomycin at concentration ranging from about 1% to about 2%, preferably about 1% wt/wt; sodium pyruvate at concentration ranging from about lOmM to about 500mM, preferably about lOOmM; nonessential amino acid is L-glutamine at concentration ranging from about ImM to about lOmM, preferably about 5mM; and HEPES ((4-(2-hydroxyethyl)-l- piperazineethanesulfonic acid) at concentration ranging from about ImM to about 20mM, preferably about
  • the coating is tumor specific and tumor is selected from group comprising stomach, colon, head & neck, brain, oral cavity, breast, gastric, gastro-intestinal, oesophageal, colorectal, pancreatic, lung, liver, kidney, ovarian, uterine, bone, prostate, testicular, glioblastoma, astrocytoma, melanoma, thyroid, bladder, non-small cell lung, small cell lung, haemotological cancers including AML [Acute Myeloid Leukemia], CML [Chronic Myelogenous Leukemia], ALL [Acute Lymphocytic Leukemia], TALL [T-cell Acute Lymphoblastic Leukemia], NHL [Non-Hodgkins Lymphoma], DBCL [Diffuse B-cell Lymphoma], CLL [Chronic Lymphocytic Leukemia] and multiple myeloma or any combinations thereof.
  • the assay is selected from group comprising assay for cell viability, cell death, cell proliferation, tumor morphology, tumor stroma content, cell metabolism, senescence or any combinations thereof.
  • the assay for the cell viability and the cell metabolism is selected from group comprising WST assay, ATP uptake assay and glucose uptake assay;
  • the assay for the cell death is selected from group comprising LDH assay, Activated Caspase 3 assay, Activated Caspase 8 assay and Nitric Oxide Synthase assay, TUNEL;
  • the assay for the cell proliferation is selected from group comprising Ki67 assay, ATP/ADP ratio assay and glucose uptake assay;
  • the assay for the tumor morphology and the tumor stroma is H&E [Haemaotxylin & Eosin staining]; or any combinations thereof.
  • the method is used for deciding treatment for the subject from group comprising chemotherapy, targeted therapy, surgery, radiation or any combinations thereof.
  • the biochemical assay is quantitative assay or qualitative assay selected from group comprising ELISA, blotting technique, LCMS, bead based assay, immuno depletion, chromatographic assay or any combinations thereof.
  • the assigning a weightage score for each of the plurality of assays is based on nature of the drug used.
  • the sensitivity index correlates to complete clinical response, partial clinical response and no clinical response when the sensitivity index is greater than 60, between 20 to 60 and less than 20 respectively.
  • the microarray and the Nucleic Acid analysis of DNA, RNA or micro RNA is carried out to detect pathway modulation before and after the drug treatment.
  • the microarray and the Nucleic Acid analysis is confirmed using assay selected from group comprising Real-time PCR (RTPCR), Immunohistochemical (IHC) analysis and phospho-proteomic profiling.
  • RTPCR Real-time PCR
  • IHC Immunohistochemical
  • the tumor microenvironment platform is selected from group comprising plate, base, flask, dish, petriplate and petridish coated with ECM composition as claimed in claim 1 optionally alongwith culture medium, serum, serum derived ligand and drug.
  • 'Sensitivity Index' and 'M-score' are interchangeably used.
  • the tumor microenvironment platform is a physical support or a base to create and/or hold the microenvironment.
  • the tumor microenvironment platform hence can be any platform which provides a physical support for culturing the tumor tissue.
  • the tumor microenvironment platform is an ex-vivo system selected from a group comprising plate, base, flask, dish, petriplate and petridish.
  • the tumor microenvironment system is created on a platform by coating it with ECM components optionally along with culture medium, serum, plasma, PBMCs, serum derived ligands and drug.
  • the serum ligands or plasma ligands or patient derived ligands or patient Peripheral Blood Mononuclear Cells is obtained from tumor/cancer patients' or subjects' blood.
  • isolation and culture of Peripheral Blood Mononuclear Cells is carried out using the below protocol. This protocol describes the method of isolation and culture of total PBMC (Granulocytes, lymphocytes, monocytes) from the peripheral blood. Approximately, about 10ml of peripheral venous blood is drawn in a heparinized container.
  • the heparinized blood is gently layered on equal volume of Histopaque 1.119 (Sigma) density gradient and is centrifuged at about 2500rpm for about 30min at about 23°C-25°C.
  • the top plasma layer is removed into sterile container and preserved for further use.
  • the cell layer is carefully removed from the interface and re- suspended in 10ml of complete medium consisting of Iscove's Modification of Dulbecco Medium (IMDM) supplemented with 20% FBS and is centrifuged at about 2000 rpm for about 8min to remove any Histopaque contamination. This step is repeated one more time to remove traces of the same.
  • IMDM Iscove's Modification of Dulbecco Medium
  • the cells After washing, the cells are re-suspended in about 5ml of complete growth medium and the cell count and viability is determined by staining Trypan Blue in a hemocytometer (where trypan blue stains only dead cells and live cells are visualized as unstained cells in the hemocytometer).
  • serum is isolated using vein-puncture technique. About 5 ml to about 7 ml of whole blood is collected on Vacuum Serum Separation Tubes (SST). Theblood is allowed to clot by standing the tube vertically in ambient temperature (about 19°C-24°C) for about 20 to 30 minutes, then centrifuged at about 2000g for about 10 minutes to separate serum from clot.
  • SST Vacuum Serum Separation Tubes
  • Clinical Response Predictor Using multiple input parameters like patients' clinical response to cancer (ca) drugs (both developed and under-development) in multiple experimental models including the explant model and human tumor xenograft model, a comprehensive patient segregation tool is developed. This tool is referred to as “Clinical Response Predictor” or as the instant Patient Segregation tool. “Clinical Response Predictor” is currently being applied to various solid cancers, both for chemotherapy and biological drugs. Additional input parameters come from the tumor's genomic, proteomic, and epigenetic matter of composition. The use of “Clinical Response Predictor” is in patient segregation. In an embodiment of the disclosure, “Clinical Response Predictor” is offered as a Lab based test.
  • “Clinical Response Predictor” is a patient segregation tool for matching drugs to patients and patients to the drugs in Oncology.
  • “Clinical Response Predictor” explant model is a personalized functional assay that helps predict the response of the patient under investigation to a set of approved drugs for his/her type of cancer. This is done using fresh patient tumor tissue from solid cancers in a specially coated 96/384 well plate. The plates are coated with specific set of Extra Cellular Matix. Further, patient derived autologous ligands are added to the culture. Angiogenic factors are added to maintain tumor vasculature. In case of immunomodulator drugs, autologus immune cells are added to the culture.
  • patient plasma is cultured in the 96/384 well format.
  • the test is carried out in multiplicates to take into account the heterogeneous nature of cancer.
  • "Clinical Response Predictor" results are measured by both kinetic as well as end-point assays.
  • Cell Viability, Cell death, Cell proliferation, cell metabolism, senescence, tumor morphology are some of the parameters assessed. Each of these parameters is measured by more than one assay. For e.g.: Cell Viability is measured by WST, ATP uptake and Glucose uptake assays.
  • Cell Proliferation and Metabolism is measured by Ki67, PCNA (proliferating nuclear cell antigen), ATP/ADP ratio and Glucose uptake.
  • Cell death is assessed by LDH, Activated Caspase 3, Activated Caspase 8 & Nitric Oxide Synthase and TUNEL.
  • Tumor morphology is assessed by H&E to look at the tumor cell content, size of the tumor cells, ratio of viable cells/ dead cells, ratio of tumor cells/ normal cells, and tumor/macrophage ratio, nuclear size and density and integrity, apoptotic bodies and mitotic figures. Results from each of the assays are expressed in numeric form and is converted using a proprietary algorithm into a single 0-100 metric called "M-score".
  • the assay takes less than a week. Thus, the result is available in time for the physician to make the treatment decision.
  • Tissue sample is excised during surgery or through punch biopsy. Sample requirement prevents the use of needle biopsy samples at present, as they are often not sufficient.
  • FIG. 1 Development of the "Clinical Response Predictor” is further depicted in Figure 1 of the present disclosure.
  • the figure details that the tumor tissue from the patient is analyzed using explant read out, primary Human tumor xenograft readout and then subjected to a variety of genomic and proteomic profiling accompanied by histological analysis and final correlation with patient clinical data for the chemotherapy regimen. All these input parameters together generate the "Clinical Response Predictor".
  • the integrated preclinical prediction model is designed based on functional "Clinical Response Predictor” screening platform and M Score prompted by it. Tumor tissues are collected from clinics prior to initiation of treatment. Clinical outcome (PERCIST/RECIST) data are collected before and after completion of 3 cycles of chemotherapy (top of the figure 1).
  • a properly validated strong M Score unlike individual components and existing standard predictors, successfully forecasts the response imminent at clinic.
  • the present disclosure describes that "Clinical Response Predictor" driven functional assay enable rapid screening of a panel of anticancer agents, captured in Table 3; example 5.
  • a panel of established and investigational anticancer agents (both cytotoxic and targeted) is selected primarily based on their known tumor growth inhibition properties. The ex vivo efficacy of these drugs are tested for a panel of patient derived explants in about 72 hours proliferation (Ki-67) and viability assay. Percent inhibition of the anti-cancer agents is determined with reference to untreated control. Inhibition above 50% is considered as complete response. Inhibition below 50% but above 20%> is considered as partial response. In non response groups, drugs that exhibit no inhibition (0%> to 20%>) is considered as no response and similar to stable diseases. Drugs that show increase in cell proliferation for a particular indication is considered as progressive diseases.
  • the present disclosure describes a patient segregation tool, that is constructed by -
  • the first step is tissue sample collection and blood sample collection post obtaining patient informed consent.
  • the samples are obtained through clinical collaboration using IRB approved procedures.
  • the tumor is obtained from the respective patient source, it is subjected to either the explants and/ or xenograft treatment method.
  • the "Clinical Response Predictor" is performed for assessment of response in primary patient tumor.
  • tumor from mice is excised and further subjected to explant analysis as described below.
  • the tumor is obtained and is implanted into the mice, thereafter it is allowed to grow, then excised and then subjected to the instant "Clinical Response Predictor" analysis.
  • tissue sample Post obtaining the, tissue sample, it is divided for obtaining various inputs from a) explant assay, b) Histology based assays like IHC (immunohistochemistry) /H&E, and c) efficacy analysis from primary tumor derived xenografts.
  • A) Tissue sample given for explant analysis is sliced using Leica Vibratome to generate sections of about 100-3000 ⁇ thickness. These sections are cultured in plates coated with the cancer type specific ECM composition in quadruplicate with media containing autologous sera and also various drugs optionally, for a period of about 48-96 hours. Media with drug and enriched with serum/plasma/PBMCs/serum derived ligands is changed every 24 hours. Post this period MTT/WST analysis is done to assess percent cell viability (end point assay).
  • the supernatant from the media culture is removed every 24 hrs and assessed for proliferation (using ATP and glucose utilization experiments) and cell death (by assessment of lactate dehydrogenase assays and caspase-3 and caspase 8 measurements) to give kinetic response trends. Results are quantified against a drug untreated control. Significantly loss in cell viability/proliferation compared to untreated control is indicative of response to drug/combination and also increased cell death. The tissue sections both treated and untreated are also given for histological evaluation at the end of the culture period.
  • tissue given for histological evaluation are assessed for apoptosis by TUNEL and activated caspase 3 assay. Also cell proliferation is assayed for standard proliferation markers like Ki67. H&E is also routinely performed to assess mitotic figures, necrosis and general gross features of the tissue.
  • xenograft study is done in order to validate the "Clinical Response Predictor" response.
  • the sample given for xenograft study is used to implant about 3-5 immuno-compromised SCID mice to generate primary tumor xenografts that are subsequently subjected to drug efficacy estimation.
  • the xenograft methodology is not a routine procedure, but is a part of the validation of the instant "Clinical Response Predictor" response.
  • the chemotherapeutics and targeted therapies tested in explant and xenograft system are identical to the regimen prescribed by the clinician for the patient from whom the tumor tissue is obtained.
  • the explant system is further validated by testing the tissue in explant system identical to the parental patient tissue and correlating the efficacy data from all these preclinical readouts, i.e readouts of the xenograft system, explant system and parental patient tissue system.
  • the time taken to generate clinical data and efficacy data for primary tumor derived xenografts is between 3-8 months. However, the turnaround time for explant analysis and histological evaluation is about 1 week.
  • All preclinical outcomes, such as cell viability, cell death by apoptosis, by cytoxicity, and also proliferation status are finally integrated to give a single score called M-score.
  • This M-score was initially built using a training cohort. It is found that low M-score is indicative of poor response whereas high M-score corresponds to better response in clinical setting. This is further validated using a validation cohort of - 100 head and neck tumors, wherein M-score for the tumors are generated and corrrelated with clinical outcome.
  • the "Clinical Response Predictor” preclinical outcome is obtained in about a week and clinical outcome is gathered after about 6 months of therapy. Thereafter, the results obtained from preclinical and clinical outcomes are correlated. The same "Clinical Response Predictor" preclinical procedure is used to identify responders and nonresponders; and it is compared to the clinical outcome in multiple solid cancers.
  • tissue samples in conjunction with the assays for "Clinical Response Predictor", can also be assessed to determine the genetic material of the tumor tissue to understand biology of the tumor.
  • the tumor tissue is subjected to nucleic acid isolation for assessing RNA and miRNA microarray analysis, gene analysis for specific mutations, exome sequencing of DNA and Genetic profiling.
  • the drug development/tumor signature/drug resistance and companion diagnostics is done in the following manner.
  • the pathways that have been affected due to drug treatment are deduced.
  • the pathways that have been modulated as a result of treatment and its effect on drug response are correlated.
  • the DNA sequence of responders and non-responders are compared to get a signature for either response or non-response. In this way, a signature for either outcome is deduced.
  • the genetic material is isolated from the resistant cells in the explants and look at the pathway modulation in comparison with the untreated samples to understand the biology behind resistance.
  • the explant read out is used to segregate responders and non-responders, and the underlying genetic information is used to reduce this to genetic signature for use as a companion diagnostic for that particular drug treatment.
  • one of the advantages of "Clinical Response Predictor” is the ability to both maintain intact tissue micro-environment and cellular architecture, while also preserving the integrity of the tumor-stroma interaction. It is in this biophysical and biochemical context that cells display bona fide tissue and organ specificity.
  • a method of explant culture using tissue slices to maintain the cellular architecture and microenvironment is described.
  • the culture media is also additionally supplemented with patient derived ligands to mimic physiologically relevant signalling pathways similar to the native environment.
  • the explant testing platform system utilizes the ECM composition that is specific for that type of cancer. In this way the explant system is a system that mimics the native host environment as closely as possible. This unique system allows us to address specific questions related to tumor signalling and the effect of small molecule inhibitors that target specific pathways within tumor environment.
  • the method of creation of local tumor micro-environment in vitro that mimics patient's tumor micro-environment is carried out.
  • the method for long term organotypic culturing of both tumor and stromal tissue is carried out, wherein said culture provides human ligands to mimic physiologically relevant signalling systems.
  • An organotypic culture comprising of human immune effectors and angiogenic factors to phenocopy tissue microenvironment of the host is done.
  • the tumor tissue is obtained from solid tumors including tumors of head & neck (HNSCC), brain, oral cavity, breast, gastric, oesophageal, colorectal (CRC), pancreatic, lung, liver, kidney, ovarian, uterine, bone, prostate, testicular, and other tissues of either human or mouse origin as well as haemotological cancers including Acute Myeloid Leukemia (AML), chronic myelogenouis leukemia (CML), Acute lymphocytic leukemia (ALL), T-cell acute lymphoblastic leukemia (TALL), non-hodgkins lymphoma (NHL), diffuse Bcell lymphoma (DBCL) and chronic lymphocytic leukemia (CLL).
  • HNSCC head & neck
  • CML chronic myelogenouis leukemia
  • ALL Acute lymphocytic leukemia
  • TALL T-cell acute lymphoblastic leukemia
  • NHL non-hodgkins lymphoma
  • the organotypic culture is for maintaining tumor tissue viability and signalling network by culturing said tissue in plates pre-coated with a cocktail of extra cellular proteins or defined Extra Cellular Matix specific for the stage and type of cancer obtained from a tissue type selected from the group consisting of cancers of head & neck, oral cavity, breast, ovary, uterus, gastro-intestinal, colorectal, pancreatic, prostate, glioblastoma, astrocytoma, melanoma, thyroid, kidney, bladder, non-small cell lung, small cell lung, liver, bone and other tissues of either human or mouse origin.
  • a cocktail of extra cellular proteins or defined Extra Cellular Matix specific for the stage and type of cancer obtained from a tissue type selected from the group consisting of cancers of head & neck, oral cavity, breast, ovary, uterus, gastro-intestinal, colorectal, pancreatic, prostate, glioblastoma, astrocytoma, melanoma, thyroid, kidney,
  • the organotypic culture is supplemented with ligands isolated from human serum, wherein the serum is autologus human serum, heterologus human serum. Further, the organotypic culture is supplemented with autologus human serum or heterologus human serum or with ligands isolated from autologus human plasma or with ligands isolated from heterologus human plasma or with ligands isolated from autologus human blood or with ligands isolated from heterologus human blood or with ligands isolated from non-human serum, plasma or blood or with PBMCs isolated from autologous blood . In yet another embodiment, the organotypic culture is also supplemented with immune factors isolated from human blood such that it is from autologus human blood or from heterologus human blood.
  • the organotypic culture is supplemented with autologus human plasma or with heterologus human plasma or with autologus human blood or with heterologus human blood or with immune factors isolated from non human serum, plasma or blood.
  • the organotypic culture is also supplemented with angiogenic factors isolated from human serum such as autologus human serum, heterologus human serum.
  • the organotypic culture is supplemented with angiogenic factors isolated from non human serum, plasma or blood or with commercially available angiogenic factors.
  • tissue in said organotypic culture is viable for greater than 7 days in culture.
  • the said culture conditions and tumor tissue are also used to study signaling networks.
  • the tumor tissue in the organotypic culture is excised and processed to maintain maximal tissue viability.
  • the said organotypic culture is also used for screening, culture and ex vivo expansion of cancer cells.
  • further processing and cryopreserving of the resulting organotypic culture is also done.
  • the application of the instant tumor microenvironment is in the selection of the optimal treatment option for the pateint under investigation.
  • the tumor microenvironment is also used in - selection of anti-cancer drugs for the patient under investigation, selection of anti-cancer drugs to combine with the drugs that has been selected for the patient under investigation, deciding the treatment option for the patient from among chemotherapy, targeted therapy, surgery, radiation or a combination thereof, deciding whether the patient will respond to chemotherapy, targeted therapy, surgery, Radiation or a combination thereof, selection of non-cancer drugs for the treatment of cancer patient under investigation.
  • the application of the instant tumor microenvironment is in the development of anticancer drugs.
  • the tumor microenvironment is also used - in the preclinical or clinical development of anti-cancer drugs, to identify the types of cancers for which the anti-cancer drug under investigation has optimal activity, to identify the optimal standard of care drugs that can be combined with the anti-cancer drug under investigation to provide optimal activity, to identify the optimal doses for the anti-cancer drug under investigation to provide optimal activity, to identify the optimal doses for standard of care drugs that can be combined with the anti-cancer drug under investigation to provide optimal activity, to identify the optimal patients who can be administered the anti-cancer drug under investigation to provide optimal activity either alone or in combination with standard of care drugs.
  • the application of the instant tumor micro-environment is in the development of companion diagnostic tests for chemotherapies, targeted drugs.
  • the tumor microenvironment is also used - in the development of companion diagnostic tests for chemotherapeutics or targeted drugs including biologies, to establish the "responders and non-responders" for chemotherapeutics or targeted drugs including biologies, molecular profiling of the thus selected "responders and non-responders” for chemotherapeutics or targeted drugs including biologies, which is used to develop the companion diagnostic test to pre-select the patients likely to respond to the chemotherapeutic or targeted drugs including biologies, as a functional companion diagnostic test to pre-select the patients likely to respond to the chemotherapeutic or targeted drugs including biologies.
  • the application of the instant patient segregation tool is also in the development of drugs for auto-immune diseases and inflammatory disorders and in the development of companion diagnostic tests for the drugs used for auto-immune diseases and inflammatory disorders.
  • a method for screening tumor cells for the presence of specific markers comprises of IHC and other techniques; and determining the viability of said cells, wherein growth and proliferation are indicative of tumor status.
  • a method for screening agents for their effect on tumor comprises act of contacting candidate agents with a culture and determining the effect of said agent on the tumor cells in said culture.
  • the aforementioned methods/applications uses tissue slice which is from human origin or from animal origin. Further, said tissue is from the central nervous system, bone marrow, blood (e.g. monocytes), spleen, thymus heart, mammary glands, liver, pancreas, thyroid, skeletal muscle, kidney, lung, intestine, stomach, oesophagus, ovary, bladder, testis, uterus or connective tissue.
  • said cells are stem cells or the cells are from more than one organ or the cells are from a healthy organ or organs or the cells are from a diseased organ or organs or the cells have been genetically altered or the cells are from a transgenic animal organ.
  • the present disclosure relates to a method for screening tumor cells for specific markers comprising act of - culturing the subject's tumor tissue on the present tumor microenvironment platform as claimed in claim 3 and treating the cultured tumor tissue with the drug(s) to assess tumor response to the drug by plurality of assays to obtain assessment score for each of the plurality of assays. Thereafter microarray analysis of mRNA and micro RNA is done to detect pathway modulation post treatment compared to pre treatment profile to identify putative biomarkers; confirmation of the same of targets is done using RTPCR and IHC.
  • Example 1 relates to preparation and coating of suitable ECM composition on cell plates which is used in the instant "Clinical Response Predictor” analysis.
  • the setup of the "Clinical Response Predictor” analysis system is elaborated in Example 2.
  • Examples 1 and 2 also illustrate the significance of coating the plates for the instant analysis with cancer specific ECM and adding serum derived ligands in the instant "Clinical Response Predictor” process.
  • Example 3 provides the Explant protocol (i.e protocol of the "Clinical Response Predictor") wherein the source of the tumor tissue can be either from the patient or xenograft thereof; and the methodology of generating the xenograft tumor tissue is provided in Example 4.
  • Example 5 presents the protocol used for determining therapeutic efficacy of drugs in tumor xenografts of SCID/nude mice, in order to validate the results obtained by "Clinical Response Predictor” Analysis.
  • the “Clinical Response Predictor” system is then subjected to preclinical validation as illustrated in Example 6 and clinical validation in Example 14.
  • the protocols of the assays employed in the "Clinical Response Predictor” Analysis have been provided in Example 7 and the concept of M score is presented in Example 8.
  • the “Clinical Response Predictor” system is further tested to predict the response of multiple solid cancers in Examples 9, 13 and 14.
  • Example 10 shows the entire protocol of "Clinical Response Predictor” comparing the results obtained with clinical outcome in order to validate the instant analysis.
  • Example 1 1 and 12 provide for experimental data in order to showcase that the instant "Clinical Response Predictor” analysis is a better response predictor than biomarkers cell lines respectively.
  • Source of the tumor is primary tumor tissue from patient, derived by standard protocols.
  • primary human tumor tissue is implanted sub-cutaneously in immune- compromised SCID mice to generate primary human tumor xenografts for a variety of solid cancers..
  • tumor is excised from the xenograft.
  • ECM is isolated from either patient tumor or from xenograft tumor tissue according to the protocol protocol provided below.
  • Surgically removed fresh tumor tissues are dissected, cut into l-2mm sections, and suspended in dispase solution (Stem cell Technologies Inc.) and incubated for 15min at 48°C.
  • the tissues are homogenized in a high salt buffer solution containing 0.05M Tris pH 7.4, 3.4M sodium chloride, 4mM of EDTA, 2mM of N-ethylmaleimide and protease (Roche) and phosphatise inhibitors (Sigma).
  • the homogenized mixture is centrifuged at 7000g for 15min and supernatant is discarded.
  • the pellet is incubated in 2M urea buffer (0.15M sodium chloride and 0.05M Tris pH 7.4) and stirred overnight at 48°C.
  • the mixture is then finally centrifuged at 14,000g for 20min, and resuspended in the 2M urea buffer and stored at -80°C in aliquots.
  • Protein estimation is done using DC protein assay kit (modified Lowry, Bio-Rad) to estimate the quantity of ECM proteins isolated for quantification. Coating of tissue culture dishes are carried out with protein extracts at 37°C for 3hr.
  • Obscurin-like protein 1 isoform 1
  • Obscurin-like protein 1 isoform 2
  • Obscurin-like protein 1 isoform 3
  • the table below lists the components of ECM that have been isolated from breast tumors and analyzed by LCMS.
  • the table below lists the components of ECM that have been isolated from head and neck squamous cell carcinoma tumors and analyzed by LCMS.
  • the table below lists the components of ECM that have been isolated from pancreatic tumors and analyzed by LCMS.
  • the table below lists the components of ECM that have been isolated from ovarian tumors and analyzed by LCMS.
  • the table below lists the components of ECM that have been isolated from glioblastoma tumors and analyzed by LCMS.
  • the 'B' prefixed proteins are Basement membrane proteins; 'C prefixed proteins are Cytoskeletal proteins; 'R' prefixed proteins are regulatory proteins; 'M' prefixed proteins are Matrix Proteins; and ' O' prefixed proteins are Others'.
  • the ECM mix for the specific cancer type is prepared by adding individual ECM proteins and other relevant constituents; and mixing the contents to form cocktail (cancer specific).
  • ECM coating on about 96 well plates is achieved by using applicator sticks to uniformly coat the sides of the well.
  • about 200 ⁇ 1 of ECM extract is added to the each well and allowed to dry for about 2 firs in an incubator at about 37°C.
  • the coated plates are washed thrice with sterile 1XPBS and stored at about -20°C for long term storage.
  • the autologous serum ligands and autologous plasma ligands and autologous PBMCs are obtained from the patient as per standard protocols.
  • Example 2.1 Addition of autologous serum ligands and ECM coating recreate tumor microenvironment in culture to mimic native tumor intracellular signaling and viability.
  • Figures 2, 3(A) and 3(B) illustrate the nature of the instant explants system which is designed to mimic host tumor micro environment as closely as possible. The primary goal is to maintain tumor tissue architecture and this is where the importance of ECM component of cell plates becomes relevant. Both structural integrity and functional integrity are crucial when it comes to understanding the biology of tumor network and in elucidating drug response or resistance. Further, the instant system is devised such that it aims at maintaining the tissue microenvironment intact both from a signalling perspective as well as structural one.
  • Autologous serum derived ligands supplemented explants culture is required for maintaining intact native signalling networks. Addition of autologous serum derived ligands maintain signalling network crucial for mimicking native tissue micro-environment ( Figure 2).
  • Panels A and B of Figure 3 are explants cultured in the absence of autologous serum derived ligands and Panels D and E are explants cultured in medium supplemented with autologous serum derived ligands.
  • FIG. 3A illustrates that plates coated with cancer type specific ECM components provide appropriate support/scaffold to help maintain intact tissue architecture which is crucial for mimicking native tissue micro-environment. Explants cultured on cancer type specific ECM components coated plates improve cell viability and provides support/scaffold to maintain tissue architecture. H&E staining of tumor tissue cultured on plates with ECM coating (panels C and E) and without (panels B and D).
  • Figure 3B shows that explants cultured in ECM coated plates along with media supplemented with autologus serum derived ligands show improved cell viability.
  • Example 2.2 Autologous ligands and Extra Cellular Matix composition retain the microenvironment and signaling network of patient tumors in culture.
  • Biopsy tumors from HNSCC patients are sectioned ( ⁇ 200micron) and cultured in 96 well plates with about 10% FBS (control) or about 2% autologous serum and about 8% FBS (Autologous serum) in RPMI media for about three days.
  • Cell viability is measured by WST assay. Percent cell viability is calculated and presented as Box and whisker plot ( Figure 4(a)). Horizontal line in the middle portion of the box denotes mean. Bottom and top boundaries are 25 th and 75 th percentiles respectively, lower and upper whiskers, 5 th and 95 th percentiles respectively. **P ⁇ 0 compared to control.
  • IHC data showing specific effect of autologous serum on proliferation of tumors is plotted as in Figure 4(b).
  • Tumors sections are stained with H&E and antibodies against Ki67 for evaluating morphological changes and cell proliferation.
  • the image magnification is 20X.
  • Figure 4(c) shows the effects of Extra Cellular Matix composition on tumor viability.
  • Inner surface of culture plate is coated with gelatin, collagen, matrigel or Extra cellular Matrix (ECM) isolated from HNSCC and tumor sections are cultured for 3 days.
  • Cell viability is measured by WST and percent cells viable is calculated (mean + s.e.m.). * ⁇ O.Olcomapred to T72 control (analysis of variance).
  • n S.
  • Figure 4(d) shows IHC profiles of explant tumors at about 3 days post culture in presence of ECM composition. H&E (left) and Ki-67(right). Ki-67 score implying the better effect of ECM composition compared with other types matrix support as indicated in Figure 4(e).
  • Example 2.3 Composition of ECM and its effects on the viability and proliferation.
  • Extra Cellular Matix composition ECM is coated on plates before culturing of tumor tissue as per the percent composition of the components of ECM indicated in Figure 5(a). Explants are cultured for about 72 hours in plates coated with different doses (1, 10 and 100 ⁇ g/ml) of ECM isolated from heterologous human tumor sources. Percentage of tumor cell viability (mean+s.e.m) is measured by WST. * ⁇ 0.05, **P ⁇ 0.01 compared to the TO and T72 control respectively by ANOVA. As seen in Figure 5(b) ECM increases the viability of tumors in a dose dependent manner.
  • Example 2.4 Comparison of the effects of different ECM Composition on proliferation and activating cancer signalling proteins.
  • Explant Protocol 1. About 3x3x3 mm small pieces of tumor slice (all uniform size and free of necrotic mass) is generated.
  • Tumor sample is divided into multiple small pieces using Leica Vibratome to generate about 100-3000 ⁇ sections and cultured in triplicate in 96 well flat bottom plates that have been previously coated with appropriate ECM composition.
  • Tumor tissues are maintained in conditioned media of about 2ml (DMEM supplanted with about 2% heat inactivated FBS along with 1% Penicillin-Streptomycin, sodium pyruvate lOOmM, nonessential amino acid, L-glutamine 4mM and HEPES lOmM.
  • the culture media is supplemented with about 2% serum derived ligands or about 2% of plasma derived ligands after 12 hours or about 100,000 PBMCs per 96 well is seeded with about 10% of autologous plasma and cultured for about 72hrs at about 37°C with about 5% C0 2 under humid conditions.
  • the media is changed every 24 hours along with supplements.
  • the tissue is asseSsed for various parameters. Post this period MTT/WST analysis is performed to assess percent cell viability. The supernatant from the media culture is removed every 24 hrs and assessed for proliferation (using ATP and glucose utilization experiments) and cell death (by assessment of lactate dehydrogenase assays and caspase-3 and caspase 8 measurements) to give kinetic response trends. Results are quantified against a drug untreated control. Significantly loss in cell viability/proliferation compared to untreated control is indicative of response to drug/combination and also increased cell death. The tissue sections both treated and untreated are also given for IHC and histological evaluation at the end of the culture period.
  • tissue given for histological evaluation are assessed for apoptosis by TUNEL and activated caspase 3 assay. Also cell proliferation is assayed for standard proliferation markers like Ki67. H&E is also routinely performed to assess mitotic figures, necrosis and general gross features of the tissue.
  • Example 4 Once the ECM composition is determined and it is coated onto the wells, the tumor from the patient or the xenograft source is subjected to explant analysis. To generate human tumor xenograft for explants analysis, the tumor is initially implanted into the SCID mice and thereafter the excised tumor is subjected to explants protocol and "Clinical Response Predictor" anaylsis. The protocol for the same is provided below:
  • mice body surface is rinsed, it is placed (ventral side down) in a properly sized nose cone or on the lid of the mice cage with dorsal side facing upwards.
  • gauze square saturated with about 70% (vol/vol) ethanol wipe the area from the mid-spine to the base of the tail to prepare for the insertion of tumor with trochar.
  • mice Properly mark the mice using nontoxic material (head/ body/tail/no mark etc.).
  • Palpable tumor (about 50mm 3 ) is noticed first and then it starts growing.
  • Removed tumors are divided into multiple pieces for different studies. Additionally, potential metastasis sites such as lungs and lymph nodes, abdomen and in select cases brain are removed and sent in formalin.
  • mice from PI or subsequent passage (PI or P N , N> I) for efficacy studies.
  • mice Monitor the mice daily and measure the tumor growth weekly, using caliper measurement as described below.
  • Tumor volume is calculated using the following formula:
  • dose the animals with appropriate drug about 1 dose/week for about 5 weeks. Monitor the mice daily and measure the tumor growth bi-weekly, using caliper measurement as described above.
  • mice Following the animals for about 4 weeks post treatment for tumor regression/growth. 5.
  • Tumor xenografts generated from tumors are known to be similar to patient tumor and hence efficacy read out obtained from such a system is indicative of patient's response to that treatment.
  • sensitivity of HTX when treated with drug combinations is very similar to response outcome from explant for the same tumor indicating that the "Clinical Response Predictor" explant system has high degree of predictability of the patients' response to drugs or combination of drugs. The same is been illustrated by the following sub-examples:
  • Example 6.1 Early passages of human tumor xenografts retain molecular characteristics of original tumors.
  • Figure 7(A) illustrates 3D PC A plot generated by Genespring GX software to show the tight clustering of samples of same origin and serial passage. The plot shows about 6 distinct clusters comprising of about 4 pairs of colon carcinoma and about 2 pairs of HNSCC samples. Unsupervised two dimensional hierarchal clustering of colon cancer and FTNSCC is illustrated in panel B of Figure 7.
  • Example 6.2 Tumor explant culture derived from early passages of human tumor xenograft and patient tumor exhibits identical antitumor effect.
  • Tumor explant culture derived from early passages of human tumor xenograft and patient tumor exhibits identical antitumor effect.
  • Explants derived from primary donor tumors (P0) and post grafts (PI and P2) generated from it are treated with TPF (Cip latin, Docetaxel, 5FU) or DMSO [Dimethyl Sulfoxide] as control.
  • TPF Cip latin, Docetaxel, 5FU
  • DMSO Dimethyl Sulfoxide
  • Figure 9(c) shows tumor growth inhibition in vivo. The same patient tumors are grown in immunocompromized mice. Tumor bearing mice are treated daily with normal saline (Control) and (TPF) for 21 days. Tumor volumes are measured at indicated time points. Data are mean tumor volume +s.e.m of 6 mice per groups. *'p ⁇ 0.001 compared with corresponding vehicle control.
  • Tumors are dissected, weighed and percent residual tumors are calculated. Representative IHC features of tumors at the end of treatment are illustrated in Figure 9(d). Tumors dissected from euthanized mice from both control and TPF groups are embedded, sectioned and stained with H&E, Ki-67 and TUNEL as indicated. Scale bars, 50 ⁇ and insets ⁇ . Biopsy tumors from HNSCC patients are sectioned ( ⁇ 200micron) and cultured in ECM coated 96 well plates with about 2% autologous serum and about 8% FBS in DMEM media for three days with DMSO (Control) and Cetuximab. Cell viability is measured by WST.
  • Figure 9(g) represents the tumor growth inhibition in Cetuximab treated mice.
  • HNSSC tumors used for Cetuximab explant culture are grown in immunocompromised mice and treated with normal saline (Control) or Cetximab (Treated) three times a week for about 23 days. Tumor volumes are measured at indicated time points. Data are mean tumor volume +s.e.m of 10 mice per groups. *'p ⁇ 0.001 compared with corresponding vehicle control.
  • Figure 9(h) represent IHC data highlighting molecular changes akin to tumor inhibition in vivo. Tumors are harvested from euthanized mice about 6 hours after the last dose of Cetuximab. Tumor sections are stained with H&E, Ki-67, TUNEL and p-ER . Scale bars 50 ⁇ , and insets ⁇ .
  • Example 6.3 Correlation of "Clinical Response Predictor” guided drug response platform with efficacy in vivo.
  • Example 7.1 Assays For Determining Cell Viability:
  • Tissue slices are incubated with 5 mg/mL of MTT at 37°C for 4 hours, harvested, and precipitated-salt extracted by incubation with 0.1 M HC1- isopropyl alcohol at room temperature for 25 min.
  • a viability value is determined by dividing the optical density of the formazan at 570 nm by the dry weight of the explants.
  • Baseline samples (TO) are used as calibrators (l x) to normalize inter sample variation in absorbance 5 readings, and tissue viability is expressed as a percentage of viability relative to TO samples.
  • tissue slices in explants are incubated with media containing different drugs at peak plasma concentration for up to 72hrs. Media containing drugs are changed every 24 hrs and MTT is performed at the T72 and TO time point as usual. To assess drug efficacy, tissue viability at the end of the study period is graded relative to tissue0 viability at the TO time point wherein the tissue is not exposed to any drug.
  • tissues are cut precisely into equal sections by vibratome (400 micron slice) and cultured in RPMI 1640 [RPMI - Roswell Park Memorial Institute] at concentration ranging5 from about 60% to about 100%, preferably about 80%>; for up to 72 hours. Tissue viability is assessed using an WST ASSAY.
  • RPMI 1640 RPMI - Roswell Park Memorial Institute
  • Tissue viability is assessed using an WST ASSAY.
  • CCK-8 cell counting kit-8, Dojindo Laboratories, Japan
  • CCK-8 cell counting kit-8, Dojindo Laboratories, Japan
  • Adenosine-5 '-triphosphate is a central molecule in the chemistry of all living things and is used to monitor many biological processes. ATP utilization is studied using the StayBriteTM ATP Assay Kit (Bio Vision). An accurate, reliable method to detect minute ATP levels is the Luciferase/Luciferin. The assay is fully automated for high throughput (1 sec/sample) and is extremely sensitive and is ideal for detecting ATP production.
  • Standard Curve To calculate absolute ATP content in samples, an ATP standard curve is generated. Add about 10 ⁇ ATP stock solution to about 990 ⁇ of Lysis buffer to make about 10 ⁇ 4 M ATP solution, into a tube labeled SI, then make about 3 - 5 more 10 fold dilutions (i.e. about 10 ⁇ + about 90 ⁇ Lysis Buffer to generate S2, S3, S4, containing about 10 "5 M, about 10 "6 M, about 10 "7 M ATP, etc.). Measurement: Add about 10 ⁇ of sample or standard into 96-well plate. Add about 90 ⁇ of the prepared Reaction Mix into the wells, mix then read luminescence (L).
  • Sa is sample amount (in pmol) from standard curve.
  • Sv is sample volume (in ⁇ ) added into the sample wells.
  • Lactose Dehydrogenase is done using LDH Cytotoxicity Assay Kit (Cayman).
  • LDH catalyzes the reduction of NAD + to NADH and H + by oxidation of lactate to pyruvate.
  • diaphorase uses the newly-formed NADH and H + to catalyze the reduction of a tetrazolium salt (INT) to highly-colored formazan which absorbs strongly at 490-520 nm.
  • INT tetrazolium salt
  • the amount of formazan produced is proportional to the amount of LDH released into the culture medium as a result of cytotoxicity.
  • Plate Set Up Each plate should contain a standard curve, wells without cells, and wells containing cells with experimental treatment or vehicle.
  • the 96-well tissue plates are centrifuged at about 400xg for five minutes. Using a new 96- well plate transfer about 100 ⁇ of the standards prepared above into the appropriate wells. Transfer about 100 ⁇ of each supernatant from each well of the cultured cells to corresponding wells on the new plate. Add about 100 ⁇ of Reaction Solution to each well using a repeating pippettor. Incubate the plate with gentle shaking on an orbital shaker for about 30 minutes at room temperature. Read the absorbance at about 490 nm with a plate reader.
  • the CPP32/Caspase-3 Fluorometric Protease Assay Kit (Bio Vision) is used for assaying the DEVD-dependent caspase activity.
  • the assay is based on detection of cleavage of substrate DEVD-AFC (AFC: 7-amino-4-trifiuoromethyl coumarin).
  • Count cells and pellet about 1-5 x about 106 cells or use about 20-200 ⁇ g cell lysates (depending on the apoptosis level).
  • tissue is homogenized in Lysis Buffer (for IX volume of tissue, add about 3X volume of lysis buffer) to generate tissue lysate, then follow the kit procedure. 3. Resuspend cells in about 50 ⁇ of chilled Cell Lysis Buffer.
  • FLICE/Caspase-8 Fluorometric Assay Kit (Bio Vision) is used for assaying the activity of caspases that recognize the sequence IETD.
  • the assay is based on detection of cleavage of substrate IETD-AFC (AFC: 7-amino-4-trifluoromethyl coumarin).
  • Assay Procedure 1 Induce apoptosis in cells by desired method. Concurrently incubate a control culture without induction.
  • Count cells and pellet about 1-5 x about 10 6 cells or use about 50-200 ⁇ g cell lysates if protein concentration has been measured.
  • Optimal cutting temperature (OCT) compound is mounted onto superfrost slides.
  • the cells are then incubated at about 37°C for about 20hr with staining solution (about 40mM citric acid sodium phosphate, pH 6.0, about lmg/ml 5-bromo-4-chloro-3-isolyl-b-D-galactoside [X-gal, Fisher], about 5mM potassium ferricyanide, about 5mM potassium ferrocyanide, about 150mM NaCl, about 2mM MgCl 2 ). After incubation, the cells are washed twice with PBS and viewed under bright-field microscopy for blue staining.
  • staining solution about 40mM citric acid sodium phosphate, pH 6.0, about lmg/ml 5-bromo-4-chloro-3-isolyl-b-D-galactoside [X-gal, Fisher], about 5mM potassium ferricyanide, about 5mM potassium ferrocyanide, about 150mM
  • Tumor is fixed in about 10% buffered formalin and embedded in paraffin. Tumor sections are cut (about 5 ⁇ ) and deparaffmised in xylene followed by rehydration in decreasing grades of ethanol. Sections are stained with Haematoxylin and Eosin (H&E). Antigen retrieval is done in Vector® Antigen Unmasking Solution (Citrate based, Vector Laboratories) by exposure to microwave heating for about 30 min. Slides are allowed to cool and subsequently washed in Tris buffered saline. Quenching of endogenous peroxidase is done by incubating the sections in about 3% H 2 0 2 for about 15 min. Protein blocking is carried out at room temperature for about lhr with about 10% goat serum.
  • H&E Haematoxylin and Eosin
  • TBS Tris Buffered Saline
  • Sections are incubated with primary antibody at aforementioned conditions followed by incubation with horse raddish peroxidase (HRP)- conjugated secondary antibody (SignalStain® Boost IHC Detection Reagent; Cell Signaling Technology) for lhr at RT.
  • HRP horse raddish peroxidase
  • SignalStain® Boost IHC Detection Reagent Cell Signaling Technology
  • Chromogenic development of signal is done using 3,3'- diaminobenzidine (DAB Peroxidase Substrate Kit; Vector Laboratories). Tissues are counterstained with Hematoxylin (Papanicolaous solution la; Merck).
  • Rabbit monoclonal phospho-AKT (Ser473; D9E XPTM) and Phospho- ⁇ (Thrl72) (clone 40H9, Cell Signaling Technology) is used at about 1 :50 and about 1 : 100 dilution respectively for overnight incubation at about 4°C.
  • Rabbit monoclonal phospho-S6 Ribosomal Protein (pS6RP) (Ser235/236; D57.2.2E XPTM) and phospho-PRAS40 (Thr246, C77D7) are obtained from Cell Signaling Technology and used at about 1 :200 dilution for overnight incubation at about 4°C; rabbit polyclonal GLUT1 (Abeam) at about 1 :200 dilution is used for about lhr incubation at room temperature (RT) ranging from about 25°C to about 35°C; rabbit polyclonal Ki67 (Vector Laboratories) is used at about 1 :600 dilution for about lhr at RT.
  • pS6RP Monoclonal phospho-S6 Ribosomal Protein
  • phospho-PRAS40 Thr246, C77D7
  • Induction of apoptosis is detected by staining for cleaved Caspase 3 using polyclonal anti-cleaved Caspase 3 (Asp 175) antibody (rabbit polyclonal, Cell Signaling Technology) at about 1 :600 dilution for about lhr at RT. Matched IgG isotype control is used for each primary antibody. Each slide is independently examined by two experts and scoring/grading is performed as per H score formula.
  • the basic principle that underpins this technique is the antigen-antibody reaction which is amplified and visualized.
  • the target antigen may be physically inaccessible to the antibody due to protein folding caused during fixation. This is overcome by a procedure called antigen retrieval, where heat is used to alter the protein folding and the antigens become more accessible. Quenching the endogenous peroxidase, protein block and blocking of endogenous biotin are important steps to avoid background staining and non-specific binding.
  • This standardised protocol uses a three layered detection system that involves the primary antibody (usually rabbit/mouse mAb) which binds to the target antigen; biotinylated secondary antibody (usually goat anti-rabbit IgG) which binds the primary antibody; and the avidin biotin complex (ABC; biotinylated horseradish peroxidase that binds to avidin to form a complex) which targets the biotin linked to the secondary antibody.
  • the antibodies help in detection of antigen and signal amplification.
  • the peroxidase enzyme which is present in ABC, catalyses a reaction where DAB (3,3'-diaminobenzidine) produces a brown precipitate which can be visualized under a microscope, ultimately detecting the target antigen.
  • Protein blocking is done. This and the subsequent steps require a humidified chamber (a tray with wet whatman filter paper).
  • reagent about 1 drop of solution A + about 1 drop of solution B + about 2.5 mL IX PBS. Incubate the reagent for about 30 min prior to use at room temperature. Any extra amounts can be stored at about 4°C for up to a month.
  • reagent a. Add about 75 of reagent to each tissue section and incubate for about 30 min.
  • Fresh preparation DAB substrate about 1 drop of Buffer + about 2 drops of DAB + about 1 drop of H 2 0 2 in about 2.5 mL double distilled water.
  • Terminal deoxynucleotidyl transferase dUTP nick end labeling is a method for detecting DNA fragmentation by labeling the terminal end of nucleic acids. TUNEL is used for detecting DNA fragmentation that results from apoptotic signaling cascades. The assay relies on the presence of nicks in the DNA which can be identified by terminal deoxynucleotidyl transferase or TdT, an enzyme that will catalyze the addition of dUTPs that are secondarily labeled with a marker. It may also label cells that have suffered severe DNA damage. Procedure:
  • the first step involves deparaffinization and rehydration
  • Stop/Wash buffer by adding about 1 mL stock buffer to about 34 mL dH 2 0.
  • b. Place slides in the buffer and agitate for about 15 seconds. Incubate for about 10 min at room temperature.
  • HEMATOXYLIN AND EOSIN STAIN is a popular staining method in histology.
  • H&E Haemaotxylin & Eosin staining
  • Example 7.4 Assays for Cell Proliferation.
  • the IHC assay is also used for the assays for standard proliferation markers like Ki67 and PCNA to determine the cell proliferation.
  • Example 7.6 Assays for Nucleic acid.
  • RNA extraction kit Purification of total RNA from tissues is done as per the Qiagen RNA extraction kit.
  • RNA later stabilized core biopsy and corresponding human tumor xenograft samples areare lysed using micro-dismembrator (Sartorius) according to the standard operating procedure. Total RNA isolated from pulverized tissues are subsequently assessed for integrity by bio- analyzer and nanodrop .
  • Tumor RNA (cRNA) micro array is carried out using the Agilent Sure Print G3 Human GE 8x60K Microarrays system platform (Agilent Technologies). For RNA microarray a RIN value above about 7 is used as a cut off. Approximately about 200ng RNA extracted from tumor samples or matched control are reverse transcribed finally to generate cy3/cy5 labeled amplified cRNA and is profiled using Agilent Kits and platform (Agilent Technologies). Array data are normalized using Feature extraction software and Agilent's Gene-Spring software. Further statistical analysis is carried out using software appropriate for this study. Data expressed as fold differences (both for up-regulated and down-regulated genes) compared with corresponding control.
  • a heat map is generated and relationship (similarity of genes) is elucidated among different primary tumor and xenografts tumor samples based on their response status.
  • Unsupervised array is used for generating a tree showing the relatedness of primary tumor derived from CR, PR or PD with corresponding xenografts based on functional profiling in the context of drug response.
  • ANOVA analysis of normalized data isperformed to distinguish the differentially expressed genes (at P ⁇ 0.05) between and among different tumors and corresponding xenograft groups.
  • REAL TIME RT-PCR Significantly expressed genes from microarray are confirmed by RT-qPCR using specific probes and primer sets using Stratagene real time PCR platform. EXOME SEQUENCING FOR MUTATION ANALYSIS.
  • Genomic DNAs are isolated from primary HNSCC tumors using DNAeasy Tissue Kit (Qiagen). Following quality check exome sequencing of the DNAs is conducted for mutation analysis as per procedures described previously. Briefly, specific sequencing primers and labeled nucleotides are to generate reaction and specific gene sequences are analyzed in Illumina Exome Sequencing platform. Differences in the mutations spectrum in clinical responder and non responder groups are determined.
  • Example 8 Generation of algorithms to predict clinical outcome:
  • tumor response to the drug is assessed by multiple assays as described in Example 6.
  • clinical outcomes are measured as per established protocols. Different weightages are given to the individual assay results of explant such that the combined score that is obtained has a linear correlation to the observed clinical outcome; i.e, high combined score (>60, for example) is correlated to complete clinical response (CR), low combined score ( ⁇ 20, for example) is correlated to clinical non-response (NR).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La présente invention concerne une composition de Matrice Extra Cellulaire spécifique pour un type de cancer, et une plateforme à microenvironnement tumoral pour une mise en culture à long terme d'un tissu tumoral, ladite mise en culture permettant à des ligands humains et à un microenvironnement de tissu tumoral d'imiter des systèmes de signalisation physiologiquement pertinents. La présente invention concerne en outre le développement d'un Dispositif de Prédiction de Réponse Clinique et son application dans le domaine du pronostic (sélection d'une option de traitement pour le patient) et les domaines de la biologie translationnelle (développement de médicaments anticancéreux). L'invention concerne en outre un procédé de prédiction d'une réponse clinique d'un patient atteint d'une tumeur vis-à-vis d'un ou de plusieurs médicaments. L'invention concerne en outre un procédé pour le criblage de cellules tumorales pour la recherche de la présence de marqueurs spécifiques pour la détermination de la viabilité desdites cellules pour une indication d'un état tumoral.
EP12838648.9A 2011-10-04 2012-10-04 Composition d'ecm, plateforme à microenvironnement tumoral et leurs procédés Active EP2764099B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3310CH2011 2011-10-04
PCT/IB2012/055334 WO2013050962A1 (fr) 2011-10-04 2012-10-04 Composition d'ecm, plateforme à microenvironnement tumoral et leurs procédés

Publications (3)

Publication Number Publication Date
EP2764099A1 true EP2764099A1 (fr) 2014-08-13
EP2764099A4 EP2764099A4 (fr) 2015-05-06
EP2764099B1 EP2764099B1 (fr) 2017-11-22

Family

ID=54261176

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12838648.9A Active EP2764099B1 (fr) 2011-10-04 2012-10-04 Composition d'ecm, plateforme à microenvironnement tumoral et leurs procédés

Country Status (14)

Country Link
US (7) US20140228246A1 (fr)
EP (1) EP2764099B1 (fr)
JP (2) JP6147259B2 (fr)
AU (1) AU2012320088C1 (fr)
CA (1) CA2850274A1 (fr)
CY (1) CY1120087T1 (fr)
DK (1) DK2764099T3 (fr)
ES (1) ES2660975T3 (fr)
HU (1) HUE036537T2 (fr)
NO (1) NO2764099T3 (fr)
PT (1) PT2764099T (fr)
SG (1) SG11201401183UA (fr)
TR (1) TR201802420T4 (fr)
WO (1) WO2013050962A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3004470B1 (fr) 2013-05-31 2018-03-14 Eaton Corporation Système hydraulique et procédé de réduction de rebond de flèche à l'aide d'une protection d'équilibrage
EP3074028B1 (fr) * 2013-11-27 2022-04-06 Research Foundation Of The City University Of New York Compositions de curcumine à activité améliorée et méthodes d'utilisation
CN103966168B (zh) * 2014-05-19 2017-05-03 广州恒迪生物科技有限公司 肿瘤活组织体外培养系统及培养方法
US10745667B2 (en) 2015-03-23 2020-08-18 Yao Tang Methods of primary tissue culture and drug screening using autologous serum and fluids
GB2555252A (en) * 2015-04-22 2018-04-25 Ono Pharmaceutical Co Method for extracting lead compound, method for selecting drug discovery target, device for generating scatter diagram, and data visualization method
GB201507894D0 (en) * 2015-05-08 2015-06-24 Imagen Biotech Ltd Personalised media
CA2999054A1 (fr) 2015-10-20 2017-04-27 Celcuity Llc Procedes de preparation d'un echantillon cellulaire primaire
CN106047788A (zh) * 2016-08-22 2016-10-26 上海逍鹏生物科技有限公司 一种适用于高密度细胞培养体系的培养基
GB2555787A (en) * 2016-11-07 2018-05-16 Landberg Goran Diagnostic methods
CA3052987A1 (fr) * 2017-02-08 2018-08-16 Mitra Rxdx, Inc. Methode de prediction de resultat clinique d'agents anticancereux
BR112019020953A2 (pt) 2017-04-05 2020-05-05 Yeda Res & Dev sistema de cultura ex-vivo e métodos de uso do mesmo
IL257225A (en) 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
WO2019164951A1 (fr) * 2018-02-22 2019-08-29 Mitra Rxdx, Inc. Procédés de prédiction de réaction à une polythérapie à séquence temporelle
GB201818885D0 (en) * 2018-11-20 2019-01-02 Precomb Therapeutics Ag 3d human cancer model-based combinatiorial drug development method
WO2020172592A1 (fr) * 2019-02-22 2020-08-27 Mitra Rxdx, Inc. Procédé de prédiction de réponse d'un patient à un médicament anticancéreux à partir d'un rapport de niveaux d'expression de deux ensembles de gènes
CA3130930A1 (fr) * 2019-03-19 2020-09-24 Kyuson Yun Procedes et systemes d'evaluation d'echantillons cellulaires
CN112961830A (zh) * 2021-02-25 2021-06-15 重庆医科大学附属口腔医院 口腔鳞癌组织脱细胞基质及其制备方法和应用
IL309061A (en) 2021-06-06 2024-02-01 Yeda res & development co ltd Combined cancer treatment
CN113774025B (zh) * 2021-08-26 2023-07-14 湖南丰晖生物科技有限公司 一种结直肠癌顺铂耐药株的构建方法
WO2023067582A1 (fr) * 2021-10-23 2023-04-27 Mazumdar Shaw Medical Foundation Plateforme de micro-environnement tumoral comprenant un carcinome buccal pour prédire la sensibilité aux médicaments, la pharmacorésistance et la progression de la maladie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508188A (en) * 1994-01-21 1996-04-16 The Regents Of The University Of California Method of growing cells in a mammal
FR2842822B1 (fr) * 2002-07-26 2004-10-01 Roussy Inst Gustave Procede de preparation d'une matrice extracellulaire et son utilisation pour la culture de cellules tumorales
US8071135B2 (en) * 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
WO2010120329A1 (fr) * 2009-04-15 2010-10-21 The University Of Medicine And Dentistry Of New Jersey Microenvironnement tumoral reconstitué pour le développement de médicaments anticancéreux
US20130071864A1 (en) * 2010-05-25 2013-03-21 Makoto Watanabe Colorectal cancer marker vitronectin and method for analyzing vitronectin concentration in blood sample

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHRIS S. HUGHES ET AL: "Matrigel: A complex protein mixture required for optimal growth of cell culture", PROTEOMICS, vol. 10, no. 9, 16 May 2010 (2010-05-16), pages 1886 - 1890, XP055081148, ISSN: 1615-9853, DOI: 10.1002/pmic.200900758 *
CHRIS S. HUGHES ET AL: "Matrigel: A complex protein mixture required for optimal growth of cell culture; Supporting Information", PROTEOMICS, vol. 10, no. 9, 16 February 2010 (2010-02-16), pages 1886 - 1890, XP055178806, ISSN: 1615-9853, DOI: 10.1002/pmic.200900758 *
N. E. CAMPBELL ET AL: "Extracellular Matrix Proteins and Tumor Angiogenesis", JOURNAL OF ONCOLOGY, vol. 72, no. 6, 1 January 2010 (2010-01-01), pages 787 - 13, XP055178652, ISSN: 1687-8450, DOI: 10.1016/S0945-053X(02)00010-0 *
SANDRA Z HASLAM ET AL: "Tumour-stroma interactions Reciprocal regulation of extracellular matrix proteins and ovarian steroid activity in the mammary gland", BREAST CANCER RESEARCH, vol. 3, no. 6, 2 August 2001 (2001-08-02), pages 365 - 372, XP055178653, ISSN: 1465-5411 *
See also references of WO2013050962A1 *

Also Published As

Publication number Publication date
DK2764099T3 (en) 2018-02-26
EP2764099B1 (fr) 2017-11-22
AU2012320088C1 (en) 2016-03-17
JP2017061448A (ja) 2017-03-30
JP2014534809A (ja) 2014-12-25
NO2764099T3 (fr) 2018-04-21
US20190353640A1 (en) 2019-11-21
AU2012320088B2 (en) 2015-07-02
CY1120087T1 (el) 2018-12-12
ES2660975T3 (es) 2018-03-26
CA2850274A1 (fr) 2013-04-11
AU2012320088B9 (en) 2015-07-16
US20190170730A1 (en) 2019-06-06
JP6378273B2 (ja) 2018-08-22
US20140228246A1 (en) 2014-08-14
HUE036537T2 (hu) 2018-07-30
TR201802420T4 (tr) 2018-03-21
SG11201401183UA (en) 2014-09-26
US20190383796A1 (en) 2019-12-19
JP6147259B2 (ja) 2017-06-14
WO2013050962A1 (fr) 2013-04-11
AU2012320088A1 (en) 2014-05-01
US20190346428A1 (en) 2019-11-14
EP2764099A4 (fr) 2015-05-06
US20200064333A1 (en) 2020-02-27
PT2764099T (pt) 2018-02-28
US20190383795A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
US20200064333A1 (en) Ecm composition, tumor microenvironment platform and methods thereof
JP6580546B2 (ja) 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法
JP6599334B2 (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
Pan et al. Targeted TPX2 increases chromosome missegregation and suppresses tumor cell growth in human prostate cancer
Lin et al. RETRACTED ARTICLE: MicroRNA 628 suppresses migration and invasion of breast cancer stem cells through targeting SOS1
CN110662844A (zh) 用于肺癌的诊断的生物标志物
Skarlos et al. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial
Onoda et al. Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors
Chiappori et al. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer
WO2019057913A1 (fr) Méthode et kits pour le pronostic du carcinome squameux pulmonaire (scc)
JP2021508835A (ja) 腫瘍細胞中のＲＡＤ５１ ｆｏｃｉの検出に基づく方法
Huang et al. Periostin facilitates ovarian cancer recurrence by enhancing cancer stemness
US20170321283A1 (en) Methods of diagnosing cancer and of predicting response of cancer to dendrogenin a treatment
Zhai et al. The relationship between the expressions of tumor associated fibroblasts Cav-1 and MCT4 and the prognosis of papillary carcinoma of breast.
WO2019057919A1 (fr) Méthodes et trousses pour le pronostic de l'adénocarcinome du poumon
CN108387742B (zh) 用于检测转运的生物传感器及其应用
Lund-Iversen Prognostic, diagnostic and predictive value of various proteins and mutations in lung carcinomas
Teng et al. Elucidating the Correlation between Leupaxin as a Prognostic Biomarker and Immunotherapeutic Efficacy in Esophageal Squamous Cell Carcinoma
Teng et al. Leupaxin: A Prospective Therapeutic Target for Esophageal Squamous Carcinoma Treatment
Wei et al. Radiation-induced sarcoma in the head and neck region: a clinicopathologic and immunohistochemical study of 13 cases
Gharpure Molecular Determinants Of Residual Disease In Ovarian Cancer
Arentz Proteomic and molecular analysis in colorectal cancer: validation of the biomarkers desmin, SET and CK8.
Awaji Utilization of High Throughput Screening to Identify Therapeutic Targets for Defective MCPH1/BRIT1 Function-Induced Premature Chromosome Condensation in Breast and Ovarian Cancer.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140328

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150407

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/78 20060101ALI20150330BHEP

Ipc: C12N 5/00 20060101ALI20150330BHEP

Ipc: C12N 15/09 20060101AFI20150330BHEP

17Q First examination report despatched

Effective date: 20160205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170331

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MITRA RXDX INDIA PRIVATE LIMITED

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 948411

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012040182

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180221

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2764099

Country of ref document: PT

Date of ref document: 20180228

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20180222

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2660975

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180326

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171122

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20171122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171122

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171122

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180222

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171122

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180400502

Country of ref document: GR

Effective date: 20180627

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E036537

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171122

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171122

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012040182

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171122

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171122

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171122

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181004

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20190924

Year of fee payment: 8

Ref country code: PT

Payment date: 20190924

Year of fee payment: 8

Ref country code: TR

Payment date: 20190919

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20191028

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20190918

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181004

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20191029

Year of fee payment: 8

Ref country code: HU

Payment date: 20190925

Year of fee payment: 8

Ref country code: NL

Payment date: 20191026

Year of fee payment: 8

Ref country code: FI

Payment date: 20191029

Year of fee payment: 8

Ref country code: IE

Payment date: 20191028

Year of fee payment: 8

Ref country code: NO

Payment date: 20191029

Year of fee payment: 8

Ref country code: SE

Payment date: 20191029

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20191029

Year of fee payment: 8

Ref country code: GR

Payment date: 20191029

Year of fee payment: 8

Ref country code: IT

Payment date: 20191023

Year of fee payment: 8

Ref country code: FR

Payment date: 20191025

Year of fee payment: 8

Ref country code: ES

Payment date: 20191104

Year of fee payment: 8

Ref country code: BE

Payment date: 20191028

Year of fee payment: 8

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 948411

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171122

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20191104

Year of fee payment: 8

Ref country code: AT

Payment date: 20190919

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20191028

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201004

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012040182

Country of ref document: DE

REG Reference to a national code

Ref country code: NO

Ref legal event code: MMEP

Ref country code: DK

Ref legal event code: EBP

Effective date: 20201031

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20201101

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 948411

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201004

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20201004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201004

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20201031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201031

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201004

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210510

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210408

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210501

Ref country code: NO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201031

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201004

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201031

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201005

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201004

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201005

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201004

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201031

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201004